Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1691 studies found for:    N10C2
Show Display Options
Rank Status Study
1 Active, not recruiting Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
Conditions: Breast Cancer;   Cancer Survivor;   Hot Flashes
Interventions: Drug: magnesium oxide;   Other: placebo
2 Withdrawn Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Fulvestrant;   Drug: Entinostat;   Drug: Placebo
3 Completed Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA in Postmenopausal Women With Bone Predominant, Hormone Receptor Positive Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Fulvestrant + ZACTIMA;   Drug: Fulvestrant + Placebo
4 Recruiting Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2)
Condition: Advanced, Metastatic Breast Cancer
Interventions: Drug: LEE011;   Drug: Letrozole;   Drug: LEE011 Placebo
5 Recruiting Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Positive;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Systemic Chemotherapy;   Drug: Tamoxifen Citrate;   Drug: Anastrozole;   Drug: Exemestane;   Drug: Letrozole;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
6 Recruiting Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
Conditions: Estrogen Receptor Positive;   HER2/Neu Positive;   Progesterone Receptor Positive;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Docetaxel;   Drug: Carboplatin;   Biological: Trastuzumab;   Biological: Pertuzumab;   Drug: Goserelin Acetate;   Procedure: Therapeutic Conventional Surgery;   Radiation: Whole Breast Irradiation;   Other: Laboratory Biomarker Analysis;   Drug: Aromatase Inhibition Therapy;   Other: Quality-of-Life Assessment
7 Active, not recruiting Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer
Condition: Breast Cancer
Interventions: Behavioral: Lifestyle intervention;   Behavioral: Mail-based
8 Active, not recruiting Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
Condition: Metastatic Breast Cancer
Interventions: Drug: Palbociclib;   Drug: Fulvestrant;   Drug: Placebo
9 Recruiting Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Condition: Breast Cancer
Interventions: Drug: BKM120 Matching placebo;   Drug: Fulvestrant;   Drug: BKM120
10 Recruiting Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Fatigue
Interventions: Drug: armodafinil 150 mg;   Other: Placebo;   Drug: armodafinil 250 mg
11 Recruiting A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
Condition: Neoplasms, Breast
Interventions: Drug: lapatinib;   Drug: trastuzumab;   Drug: Aromatase inhibitor
12 Not yet recruiting Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
Condition: Advanced, Metastatic Breast Cancer
Interventions: Drug: LEE011;   Drug: Tamoxifen;   Drug: Letrozole;   Drug: Anastrozole;   Drug: Goserelin;   Drug: LEE011 Placebo
13 Recruiting Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
Conditions: Breast Cancer;   HER2-negative Breast Cancer;   HER2-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Carboplatin;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Drug: bevacizumab;   Drug: trastuzumab;   Procedure: magnetic resonance imaging;   Procedure: therapeutic conventional surgery
14 Completed
Has Results
Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.
Condition: Meningococcal Disease
Intervention: Biological: MenACWY-CRM
15 Recruiting A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
Condition: Breast Neoplasms
Interventions: Drug: Abemaciclib;   Drug: Fulvestrant;   Drug: Placebo
16 Completed Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery
Conditions: Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer
Interventions: Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Drug: paclitaxel;   Biological: filgrastim;   Drug: capecitabine;   Drug: methotrexate;   Drug: vinorelbine tartrate;   Procedure: needle biopsy;   Procedure: therapeutic conventional surgery;   Other: immunohistochemistry staining method;   Biological: trastuzumab;   Drug: tamoxifen citrate;   Drug: letrozole;   Other: laboratory biomarker analysis
17 Not yet recruiting Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
Condition: Breast Neoplasms
Interventions: Drug: Radium-223 dichloride (Xofigo, BAY88-8223);   Drug: Placebo (saline);   Other: Background hormonal therapy
18 Recruiting Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
Conditions: Breast Tumor;   Breast Cancer;   Cancer of the Breast;   Estrogen Receptor- Negative Breast Cancer;   HER2- Negative Breast Cancer;   Progesterone Receptor- Negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer;   Triple-negative Metastatic Breast Cancer;   Metastatic Breast Cancer
Interventions: Drug: nab-Paclitaxel 125 mg/m2 plus carboplatin AUC 2 in triple negative metastatic breast cancer (TNMBC) subjects;   Drug: Carboplatin AUC 2;   Drug: gemcitabine 1000 mg
19 Recruiting A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery
Conditions: Luminal A Breast Cancer;   Luminal B Breast Cancer;   CPS-EG Score;   Postneoadjuvant Treatment With CDK 4/6 Inhibitor;   Hormonreceptor Positive
Interventions: Drug: Palbociclib PD-0332991;   Behavioral: Patient reported outcomes;   Drug: Placebo
20 Recruiting Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Anastrozole;   Drug: Anastrozole+Fulvestrant;   Drug: Tamoxifen

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years